EICHORCondition: Stomach Neoplasms · Gastric Outlet Obstruction · Palliative Surgery · Sponsor: Gyeongsang National University Hospital
Interested? Contact the study team ↓
The goal of this clinical trial is to evaluate whether stomach-partitioning gastrojejunostomy (SPGJ) more effectively reduces postoperative delayed gastric emptying (DGE) compared to conventional gastrojejunostomy (CGJ) in patients with unresectable stage IV gastric cancer accompanied by malignant gastric outlet obstruction (MGOO). This multicenter randomized trial aims to establish a new surgical standard that enhances recovery and quality of life in advanced gastric cancer. The main questions are: 1. Does SPGJ significantly decrease DGE compared with CGJ? 2. Does SPGJ enable faster food tolerance, shorter hospital stay, and earlier chemotherapy? Researchers will compare two arms - SPGJ and CGJ - to determine differences in postoperative gastric emptying, hospital course, complications, and survival outcomes. Participants Eligible participants are adults aged 20-85 years with histologically proven unresectable gastric adenocarcinoma limited to the lower third of the stomach and endoscopic or radiologic evidence of obstruction. Patients with total bowel obstruction, middle-third tumor extension, emergency conditions, or severe malnutrition (albumin \< 2.5 g/L) are excluded. Interventions * CGJ arm: Standard laparoscopic gastrojejunostomy using a 60 mm stapler without partitioning. * SPGJ arm: Laparoscopic transverse gastric partitioning 5 cm proximal to the tumor with a 2 cm bridge at the lesser curvature, followed by stapled gastrojejunostomy. All operations follow sta…
This description comes directly from the study's public registry record.
Sang-Ho Jeong, MD, PhD · +82-55-214-3774 · shjeong@gnu.ac.kr
Ji-Ho Park, MD, PhD · +82+10-9355-0510 · goodgsdr@gmail.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma with Gastric Outlet Obstruction (GOO) that is unresectable for cure (e.g., surrounding tissue invasion, localized peritoneal metastasis, distant metastasis) * Tumor location confined to the lower one-third (Low body 1/3) of the stomach ③ Age between 20 and 85 years * ECOG Performance Status ≤ 2 ⑤ ASA score Class I to III ⑥ Endoscopic or radiologic evidence of obstructive GOO Exclusion Criteria: * Patients with bowel obstruction due to extensive peritoneal metastasis (P3) * Tumor extension beyond the lower one-third into the middle one-third of the stomach, making partitioning difficult ③ Patients requiring emergency surgery for perforation or hemorrhage ④ Severe malnutrition (serum albumin \< 2.5} g/L) ⑤ Patients currently undergoing pre-operative chemotherapy
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Gyeongsang National University Changwon hospital | Changwon, Gyeongsangnam-do, South Korea | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07749326